Ocuphire Pharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Income Taxes (Narrative) (Details) - USD ($)	3 Months Ended		6 Months Ended
Income Taxes (Narrative) (Details) - USD ($)	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Operating Loss Carryforwards [Line Items]
Provision for Income Taxes
Operating loss carry-forward	$ 160,154,000		160,154,000		$ 156,586,000
Federal And State [Member]
Operating Loss Carryforwards [Line Items]
Provision for Income Taxes			$ 0	$ 0

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.